Loading…
Neurogene Inc. is projected to rise to $50.57 by 2027, a +28% move from its current price of $39.63. NGNE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $37.81 | $39.66 | $41.61 | +0.09% |
| Jul 14 | $37.10 | $39.70 | $42.48 | +0.17% |
| Jul 15 | $36.57 | $39.73 | $43.17 | +0.26% |
| Jul 16 | $36.13 | $39.77 | $43.76 | +0.34% |
| Jul 17 | $35.76 | $39.80 | $44.30 | +0.43% |
| Jul 18 | $35.43 | $39.83 | $44.79 | +0.52% |
| Jul 19 | $35.12 | $39.87 | $45.25 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $35.12 | $39.87 | $45.25 | +0.60% |
| Week 2 | $33.53 | $40.11 | $47.98 | +1.21% |
| Week 3 | $32.40 | $40.35 | $50.25 | +1.82% |
| Week 4 | $31.51 | $40.59 | $52.30 | +2.43% |
| Week 5 | $30.76 | $40.84 | $54.21 | +3.05% |
| Week 6 | $30.12 | $41.08 | $56.03 | +3.67% |
| Week 7 | $29.56 | $41.33 | $57.79 | +4.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. Its product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. The company has license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.
LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc. (NGNE) is a healthcare stock. Its current price is $39.63 and its market capitalization is $790.63M, with a rank of 2723. The stock trades within a 30-day range that reflects ongoing activity as investors evaluate its late-stage genetic medicines for rare neurological diseases.
A major floor 51.9% below — a decisive break under it would weaken the trend.
The nearest floor, 34.0% below — buyers have tended to step in here.
The nearest ceiling, 8.1% above — a clean break opens room to run.
A major ceiling 33.5% above — clearing it would confirm fresh momentum.
Key NGNE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NGNE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $38.01 | Buy | $38.56 | Buy |
| MA 10 | $35.51 | Buy | $36.35 | Buy |
| MA 20 | $32.91 | Buy | $33.87 | Buy |
| MA 50 | $30.23 | Buy | $30.45 | Buy |
| MA 100 | $26.06 | Buy | $27.53 | Buy |
| MA 200 | $24.23 | Buy | $25.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.49 | Neutral |
| Stoch RSI (14) | 50.91 | Neutral |
| CCI (20) | 153.09 | Buy |
| Williams %R (14) | -25.14 | Info |
| MACD (12,26,9) | 0.91 | Buy |
| ROC (12) | 28.42 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 74.86 | Neutral |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 7.35 | Buy |
| Ultimate (7,14,28) | 68.13 | Neutral |
| Momentum (10) | 9.22 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 41.54 | Sell |
| ADX (14) | 23.87 | Buy |
| ATR (14) | 1.70 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 70. The 50-day simple moving average sits at $30.23 and the 200-day simple moving average at $24.23, suggesting near-term upward momentum. Support is identified at $26.14 and resistance at $42.84, framing a constructive near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.37 | $39.63 | $59.95 | 0% | Neutral | |
| $37.44 | $50.57 | $73.63 | +28% | Bullish | |
| $34.09 | $48.56 | $74.97 | +23% | Bullish | |
| $42.90 | $63.93 | $103.23 | +61% | Bullish | |
| $48.87 | $75.86 | $127.15 | +91% | Bullish | |
| $62.11 | $100.14 | $173.33 | +153% | Bullish | |
| $79.88 | $133.50 | $237.76 | +237% | Bullish | |
| $78.32 | $135.47 | $247.52 | +242% | Bullish | |
| $83.53 | $149.36 | $279.35 | +277% | Bullish | |
| $87.76 | $162.09 | $309.77 | +309% | Bullish | |
| $139.68 | $301.16 | $628.94 | +660% | Bullish | |
| $278.14 | $618.09 | $1,421.61 | +14.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.37 | $39.63 | $47.70 | +0.00% |
| August 2026 | $34.10 | $41.07 | $51.38 | +3.64% |
| September 2026 | $35.13 | $42.85 | $54.63 | +4.33% |
| October 2026 | $34.23 | $42.21 | $54.67 | -1.49% |
| November 2026 | $34.32 | $42.71 | $56.04 | +1.18% |
| December 2026 | $35.96 | $45.15 | $59.95 | +5.70% |
Click any year to see its month-by-month NGNE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NGNE to range from $16.37 to $59.95 through 2026. The $39.63 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NGNE price prediction for 2027 points to an average of $50.57 (low $37.44, high $73.63) — a potential gain of +28% on today's $39.63. Momentum favours further upside here.
In 2028, NGNE is projected to trade between $34.09 and $74.97, averaging $48.56 — a potential gain of +23% from today's $39.63. That is -4% versus the projected 2027 average. Buyers look set to stay in control over this stretch.
Neurogene Inc.'s 2029 outlook centres on $63.93, within a $42.90 to $103.23 range. That is up +32% on the projected 2028 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2030, NGNE could reach as high as $127.15, with a base case around $75.86 and support toward $48.87 — roughly +91% from $39.63. Buyers look set to stay in control over this stretch.
Expect NGNE to range from $62.11 to $173.33 through 2031. The $100.14 average target implies a +153% move from current prices. That is up +32% on the projected 2030 average. Momentum favours further upside here.
The NGNE price prediction for 2032 points to an average of $133.50 (low $79.88, high $237.76) — a potential gain of +237% on today's $39.63. Buyers look set to stay in control over this stretch.
In 2033, NGNE is projected to trade between $78.32 and $247.52, averaging $135.47 — a potential gain of +242% from today's $39.63. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Neurogene Inc.'s 2034 outlook centres on $149.36, within a $83.53 to $279.35 range. That is up +10% on the projected 2033 average. That marks a +277% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NGNE could reach as high as $309.77, with a base case around $162.09 and support toward $87.76 — roughly +309% from $39.63. Momentum favours further upside here.
Expect NGNE to range from $139.68 to $628.94 through 2040. The $301.16 average target implies a +660% move from current prices. That is up +86% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NGNE price prediction for 2050 points to an average of $618.09 (low $278.14, high $1,421.61) — a potential gain of +14.6x on today's $39.63. Momentum favours further upside here.
Investing $1,000 in NGNE today (≈ 25.233409 NGNE) could be worth
$15,596.51
+$14,596.51 (+1460%) by 2050 · US Dollar
Based on the average projected NGNE price of $618.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NGNEwould be worth at today's price.
$1,000 invested in NGNE on Jul 10, 2025 (≈ 45.537343 NGNE) would be worth
$1,804.64
+$804.64 (+80.5%) today · 1.80× · US Dollar
Based on a NGNE entry price of $21.96 vs. today's $39.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.34 | $1,121.39 | +12.1% |
| 1 month ago | $28.01 | $1,414.85 | +41.5% |
| 3 months ago | $20.38 | $1,944.55 | +94.5% |
| 6 months ago | $17.28 | $2,293.4 | +129.3% |
| 1 year ago | $21.96 | $1,804.64 | +80.5% |
| All time (5.0y) ago | $175.2 | $226.2 | -77.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NGNE forecast.
Our base-case forecast reaches $79.00 around 2031.
Implied market cap at $79.00: $1.58B
The year-by-year forecast portrays a strong long‑term uptrend with a bullish sentiment in most years. In 2026 the average price is $39.63, with a min of $16.37 and a max of $59.95 (ROI 0). The trajectory continues higher in 2027 to an average of $50.57 and a max of $73.63 (ROI 27.6); 2028 shows $48.56 (max $74.97; ROI 22.5); 2029 projects an average of $63.93 (max $103.23; ROI 61.3).
By 2030 the average reaches $75.86 (min $48.87, max $127.15; ROI 91.4), and 2031 shows $100.14 (max $173.33; ROI 152.7). The curve extends to 2032 with an average of $133.50 (max $237.76; ROI 236.9), 2033 with $135.47 (max $247.52; ROI 241.8), 2034 with $149.36 (max $279.35; ROI 276.9), and 2035 with $162.09 (max $309.77; ROI 309). Forward-looking projections escalate sharply, with 2040 an average of $301.16 (min $139.68, max $628.94; ROI 659.9) and 2050 an average of $618.09 (min $278.14, max $1,421.61; ROI 1459.7), all carrying bullish sentiment.
These figures imply substantial upside potential alongside inherent uncertainty in long‑term outcomes.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $48.87, an avg of $75.86, and a max of $127.15, with an ROI of 91.4 and bullish sentiment.
The forecast displays bullish sentiment from 2027 onward, with the average price rising from $50.57 in 2027 to $618.09 in 2050 and the ROI reaching 1459.7 in 2050, though 2026 sits at an average of $39.63 with ROI of 0.
Yes. The 2031 forecast lists an average of $100.14 and a max of $173.33, indicating a path that could exceed $100, with 2030 max at $127.15 prior to that.
The 2040 forecast shows an average of $301.16, with a min of $139.68 and a max of $628.94, and a bullish sentiment (ROI 659.9).
For 2050, the average is $618.09, with a min of $278.14 and a max of $1,421.61, and a bullish sentiment (ROI 1459.7).
Neurogene Inc. Community Discussion
0Share your Neurogene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.